Navigation Links
Firefly protein lets researchers monitor molecule linked to cancer

Scientists have used a glowing protein from fireflies to observe the activity of a molecule that is an important target for new drugs to treat cancer, autoimmune diseases and several other disorders.

The target molecule, known as IKK (for IKappa kinase), regulates processes that can trigger dramatic changes in cellular physiology. Scientists have linked these changes to many different disorders.

"Our new system allows researchers to monitor whether drugs for these conditions are hitting this exact molecular target in cell culture and laboratory animals," says senior investigator David Piwnica-Worms, M.D., Ph.D., professor of molecular biology and pharmacology and of radiology.

Piwnica-Worms and lead author Shimon Gross, Ph.D., a postdoctoral fellow, measured light from the firefly protein, luciferase, to monitor IKK activity in tumor cells and inflamed liver cells in live mice. They also showed that the technique can greatly reduce the costs of tests that establish the best dosages for drugs that target IKK. Their results appear in the August 2005 issue of Nature Methods.

IKK stands at a pivot point in the middle of an important set of linked chain reactions known as the NF-KappaB pathway. The pathway can start at many different receptors on cell surfaces; its finish changes the activity levels of varying genes. The result, according to Piwnica-Worms, is that the potential reaction patterns in the NF-KappaB pathway form an hourglass-like shape, fanning out among many options at the start, narrowing in the middle, and again fanning out among many options at the end.

"At the waist of that hourglass is IKK," he explains. "This appears to put it in a position to be the key regulator of the pathway, and that has made it a subject of great interest both from the perspective of understanding how this pathway works and from that of developing new drugs for conditions that involve this pathway. "

Piwnica-Worms' laboratory has pr
'"/>

Source:Washington University School of Medicine


Page: 1 2 3

Related biology news :

1. New, automated tool successfully classifies and relates proteins in unprecedented way
2. New binding target for oncogenic viral protein
3. Controversial drug shown to act on brain protein to cut alcohol use
4. Timing is everything: First step in protein building revealed
5. UWs Rosetta software to unlock secrets of many human proteins
6. Researchers find how protein allows insects to detect and respond to pheromones
7. Signaling protein builds bigger, better bones in mice
8. Ancient olfaction protein is shared by many bugs, offering new pest control target
9. Automatic extraction of gene/protein biological functions from biomedical text
10. Discovery of key proteins shape could lead to improved bacterial pneumonia vaccine
11. Scientists develop new color-coded test for protein folding
Post Your Comments:
(Date:7/21/2015)... GOTHENBURG, Sweden , July 21, 2015 ... sensor FPC1025. Already received as well as expected revenues in 2015 ... included in FPC,s communicated revenue guidance of approximately 2,200 MSEK for ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... OXFORD, Conn. , Jul. 13, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... it has filed provisional patent 62/188684 for ... NXT-ID achieves another new convenient and secure method ... expands new, innovative payment methods, introduced with its ...
(Date:7/8/2015)... YORK , July 8, 2015 Summary ... globally, and the fourth most fatal, with a mortality ... The poor prognosis of pancreatic cancer patients has highlighted ... treatment, which is not being met by the current ... an array of products with varying molecule types and ...
Breaking Biology News(10 mins):FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3
... team of Montral researchers at the IRCM led by Dr. ... team at Duke University in the United States, discovered that ... by affecting certain types of cognitive performance such as anxiety, ... scientific journals Proceedings of the National Academy of Sciences ...
... simple experiment, a scientist exposes rats to a certain ... symptoms remarkably similar to those seen in Parkinson,s patients. ... disease, which affects 7 million to 10 million people ... Chemical & Engineering News , the weekly newsmagazine of ...
... science team led by researchers at Scripps Institution of Oceanography ... the impact of fishing on a group of fish known ... in the journal Proceedings of the Royal Society B ... conservation targets to protect and preserve fragile coral reefs. ...
Cached Biology News:An important discovery related to anxiety disorders and trauma 2An important discovery related to anxiety disorders and trauma 3Scripps leads first global snapshot of key coral reef fishes 2Scripps leads first global snapshot of key coral reef fishes 3
(Date:7/30/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), a ... develop, and commercialize novel flavor ingredients for the food, ... for the second quarter 2015. "Moving ... track to achieve our commercial and financial goals," stated ... Company. "Since our last quarterly earnings report, our two ...
(Date:7/30/2015)... , July 30, 2015  Discovery Laboratories, ... it has received the second $1.0M tranche under ... Research (SBIR) grant valued at up to $3.0 ... aerosolized KL4 surfactant as a potential medical countermeasure ...  Discovery Labs was awarded an initial $1.0 million ...
(Date:7/29/2015)... , July 30, 2015 ... santé, publie ses résultats pour le premier semestre ... commente les résultats. Visionner l,interview vidéo ... http://www.eurobusinessmedia.com/ceo-direct/sanofi/sanofi-h1-2015-results-interview-with-ceo-olivier-brandicourt?utm_source=ceo-direct&utm_medium=wire Au sommaire de l,interview ... - Moteurs de croissance - Diabète ...
(Date:7/29/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today ... Financial Officer has resigned.  The Company has hired ... retired in December 2014, as full time interim CFO ... Andy Ashworth began his employment ... smooth transition.  Andy was the Company,s CFO from September ...
Breaking Biology Technology:SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3
... thrive in today,s,competitive and changing marketplace, sales force ... doesn,t just happen. Productive,companies train, structure, deploy, and ... to ensure high success rates., Best Practices ... sales forces to evolve and mature to capture ...
... Opportunities -, BRIDGEWATER, N.J. and NEW YORK, June ... announced,its launch backed by Warburg Pincus, the leading global ... in GANIC from Warburg,Pincus Private Equity X, L.P., a ... Pharmaceuticals was founded by a highly seasoned group of ...
... a,global point-of-care diagnostic test manufacturer and wholly owned,subsidiary ... today announced,that its HemoCue Albumin 201 System is ... and monitoring microalbuminuria to be,granted a CLIA waiver ... With,the FDA CLIA waiver, non-laboratory trained physicians and ...
Cached Biology Technology:Increasing Sales Productivity Through Superior Sales Force Performance Management 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 2GANIC Pharmaceuticals Launched with Premier Pharmaceutical Industry Executives 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 2HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 3HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 4HemoCue Receives First FDA CLIA Waiver in Diagnostics Industry for Quantitative Point-of-Care Test for Microalbuminuria, a Kidney and Cardiovascular Disease Risk Marker 5
Recombinant Viral CCI/Fc Chimera, CF...
... DeStreak Reagent, 1 ml. Improves ... gels by preventing streaking.Eliminates extra ... of proteins.Stabilizes proteins throughout entire ... well-resolved protein patterns.Ideal for both ...
LIVE/DEAD® Cell-Mediated Cytotoxicity Kit *for animal cells* *2000 assays*...
SlowFade Antifade Kit with DAPI...
Biology Products: